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Abstract
Background: Studies have shown that research participants fail to appreciate the difference
between research and medical care, labeling such phenomenon as a "therapeutic misconception"
(TM). Since research activity involving human participants is increasing in the Middle East, qualitative
research investigating aspects of TM is warranted. Our objective was to assess for the existence of
therapeutic misconception amongst Egyptians.
Methods: Study Tool: We developed a semi-structured interview guide to elicit the knowledge,
attitudes, and perspectives of Egyptians regarding medical research.
Setting: We recruited individuals from the outpatient settings (public and private) at Ain Shams
University in Cairo, Egypt.
Analysis: Interviews were taped, transcribed, and translated. We analyzed the content of the
transcribed text to identify the presence of a TM, defined in one of two ways: TM1 = inaccurate
beliefs about how individualized care can be compromised by the procedures in the research and
TM2 = inaccurate appraisal of benefit obtained from the research study.
Results: Our findings showed that a majority of participants (11/15) expressed inaccurate beliefs
regarding the degree with which individualized care will be maintained in the research setting (TM1)
and a smaller number of participants (5/15) manifested an unreasonable belief in the likelihood of
benefits to be obtained from a research study (TM2). A total of 12 of the 15 participants were
judged to have expressed a TM on either one of these bases.
Conclusion: The presence of TM is not uncommon amongst Egyptian individuals. We recommend
further qualitative studies investigating aspects of TM involving a larger sample size distinguished by
different types of illnesses and socio-economic variables, as well as those who have and have not
participated in clinical research.
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Background
For more than two decades, commentators have expressed
concerns about research participants not distinguishing
between research and clinical care [1-3]. Indeed, several
empirical studies have shown that individuals participat-
ing in clinical research misconstrue a therapeutic inten-
tion to the research procedures in a study [4-10]. The term
"therapeutic misconception" (TM) is used to describe this
phenomenon, a term first reported by Appelbaum and
colleagues in 1982 during interviews with patients with
psychiatric disorders who participated in clinical trials [1].
At its basic level, TM involves a research participant's fail-
ure to recognize the distinction between the purposes of
research and clinical care. Investigators have identified
two ways in which TM can be manifested: 1) when
research participants fail to recognize that decisions
regarding randomization or certain aspects of the research
procedures (e.g., dosages and duration of administered
drugs) will not be individualized to their personal needs
(TM1); or 2) when research participants hold an unrea-
sonable appraisal of the nature or likelihood of medical
benefit from their study participation (TM2) [4]. Essen-
tially, research participants might hold mistaken beliefs
about how the research will be executed (TM1) or is
designed in a manner to ensure direct benefits to them
(TM2) [1].
The presence of TM might be explained by participants'
knowledge gap regarding how clinical research and
patient care differ in their purpose, characteristic meth-
ods, and justification of risks [3]. Alternatively, it might be
due to participants' misplaced trust in researchers, think-
ing that they will act as their physicians who will protect
them, as well as promote their individual health interests
[11]. Accordingly, participants might believe that investi-
gators would not suggest enrollment unless it was very
likely that they would benefit from the study or that the
risks of research participation are without any substantial
degree of risk. Regardless of underlying mechanisms, eth-
ical concerns with the presence of a therapeutic miscon-
ception include the validity of informed consent (due to
false beliefs regarding the magnitude of risks and poten-
tial benefits) and exploitation leading to inappropriate
enrollment of patients into research.
Investigators have explored the frequency and the factors
(both participant- and study-related) that might underlie
the existence of TM in clinical research[4,6,7]. The identi-
fication of such factors, as well as attempts to prevent or
mitigate the TM might have limited applicability to indi-
viduals in resource-limited countries, due to the existence
of extreme poverty and lack of access to health care, high
illiteracy rates, language and cultural barriers, gender ine-
quality, and patients' enhanced unquestioning of their
physicians' trust compared with that in the Western
world. A few studies investigating the TM have occurred in
the African setting [8-10]. The aim of this study was to
assess the feasibility of investigating for the presence of
TM in an interview study involving Egyptians attending
public and private clinics. While our study is exploratory,
we expect that our findings and experience will help
towards the design of future TM studies in this type of
population.
Methods
Sample and Setting
This study used the content of the interviews obtained
from a previous pilot qualitative study exploring the
knowledge, attitudes, and perspectives of Egyptians
regarding medical research [12]. This previous study had
recruited a convenient sample of 15 individuals from the
outpatient clinic waiting areas from two of Ain Shams
University hospitals: Ain Shams University Specialty Hos-
pital, a semi-private university-based hospital; and Ain
Shams University Public Hospital, a public teaching hos-
pital. Private hospitals in Egypt serve patients with a
higher socio-economic status than the public clinics. Both
hospitals are situated in the metropolitan area of Cairo
and serve as referral hospitals for patients predominantly
coming from northern (Lower) Egypt as opposed to
southern (Upper) Egypt. Lower Egypt consists of Cairo
and areas of the Nile Delta, which fans out north of Cairo
to the Mediterranean coastline to include Alexandria and
Port Said. Urban life in Lower Egypt is marked by some
20–30 percent of the population living below the poverty
line and an illiteracy rate of approximately 55 percent.
Upper Egypt is predominantly rural and extends from 120
kilometers south of Cairo to the border with Sudan. One
third of the population and half of Egypt's poor live in
Upper Egypt and it is also the area with the highest infant
mortality rates, 36% above the national average [13].
Recruitment Process
Participants were recruited from the clinics' waiting
rooms; they were either patients waiting for their clinic
appointments or members of the lay public accompany-
ing family members who had clinic appointments.
Semi-structured interview tool
The survey tool consisted of open-ended questions that
assessed their knowledge, attitudes, and perceptions
regarding the following:
￿ clinical research
￿ their willingness to participate in different types of
research, assessed by the use of short clinical research
vignettesBMC Medical Ethics 2009, 10:7 http://www.biomedcentral.com/1472-6939/10/7
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￿ research concepts (e.g., randomization, double-
blinded, equipoise)
￿ value of informed consent
￿ motivations of researchers
Interviews
All interviews were conducted in colloquial Arabic. Inter-
views lasted approximately 45 minutes and were audio-
taped. All of the interviews were conducted during a
period of six months. Audio recordings were transcribed
in Arabic and then translated into English. Interviewers
helped participants complete a form that collected demo-
graphic information.
Analysis
We performed a content analysis by having the three
authors (MW, SSK and HJS) independently code the con-
tent of the transcripts based on the two categories of TM
that had been previously identified (a priori coding) [14].
Each author scored the relevant responses dichotomously
(0 or l) for the presence of TM1 and TM2, as defined above.
All three authors discussed and compared the responses
and differences were reconciled in iterative meetings [15].
In scoring for TM2, we made an effort to distinguish
unreasonable appraisals in the extent of direct benefits
from clinical research from two related but different con-
cepts: 1) therapeutic misestimation, which involves mis-
understanding the probability of direct benefit or harms
that might result from research participation; and 2) ther-
apeutic optimism, which involves participants hoping
that they would be one of the lucky few who would
receive a benefit [16].
Confidentiality
Participants were assigned a unique name different from
their actual name. These names were used during the
interview. This unique name was coded to the individual's
demographic form, which did not use the individual's real
name. Tapes were destroyed after they were transcribed.
Informed Consent
All participants gave their informed consent, which was
given verbally, witnessed, and documented on the tape
recording.
Ethics Approval
The research ethics committees at Ain Shams University
and the University of Maryland, School of Medicine gave
approval for the conduct of this study and approved the
mechanism of obtaining verbal consent.
Results
Demographic and background information
Of the 15 participants, 10 were female and 5 were male.
Nine were recruited from the private hospital and six were
recruited from the public hospital. Thirteen of the partici-
pants were from Lower Egypt, whereas two resided in
Upper Egypt. The age range was from 19 to 69, with a
median age of 30 and an average age of 38 years. Three
participants had completed high school, eight had an
undergraduate college degree, and four participants had
attained a degree higher than undergraduate level. Of
these participants, eight were patients waiting for their
clinic appointments, while seven were accompanying
family members to the clinic. Eight participants were mar-
ried, all with children, while seven participants were sin-
gle. All but one participant was unemployed; nine were
considered to be in the lower income bracket (less than
1000 Egyptian pounds/month or less than $175/month
total household income). For each participant who agreed
to participate in the interview study, approximately four
were approached. Common reasons given for refusal to
participate in the study included time constraints or fear
of missing their appointments.
Manifestation of the Therapeutic Misconception (TM)
Our findings showed that a majority of the participants
(11/15) expressed inaccurate beliefs regarding the degree
with which individualized care will be maintained in the
research setting (TM1). A smaller number of participants
(5/15) manifested unreasonable beliefs in the nature or
likelihood of the benefits that one could obtain in a
research study (TM2). Of these 15 participants, 12 were
judged to have expressed a TM on at least one of these
bases, whereas 4 of the 15 of the participants expressed a
TM on both of these bases.
Responses Reflected of TM1
Examples of responses that were scored as reflecting inac-
curate beliefs that care would be individualized (TM1)
included the following:
Interviewer: "Do you think the medical care you get from
a study-doctor will be the same type of care that you'll get
from a doctor who isn't doing a study?
Participant: "No, there wouldn't be a difference"
To a similar line of questioning, another participant had
the following response (a combination of TM1 and TM2):
Interviewer: Would you be concerned that they are more
concerned with the research they're doing rather than pro-
viding individualized care?"BMC Medical Ethics 2009, 10:7 http://www.biomedcentral.com/1472-6939/10/7
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Participant: "No, because the goal of research is to make
people better. They won't neglect their care, just because of
the research"
In contrast, one participant realized that his/her own phy-
sician would administer care that was more individual-
ized than that received in a research study:
Interviewer: "Do you think the medical care that you get
from a study-doctor will be the same type of care you will
get from a doctor who is not doing a study?"
Participant: "I think it would just be better care from some-
one that has known me for a long time."
When asked regarding the prospect that the study-doctor
will not know which drug would be administered to the
patient (i.e., doctor being blinded) or that administration
of the drug will be done by a random process, the follow-
ing responses suggest there was disbelief that such a proc-
ess would occur or they simply ignored what they were
being told to them:
Interviewer: "How would you feel if your doctor would not
know which drug you would be taking?"
Participant: "There's no way that my doctor doesn't know what
I'm taking"
Interviewer: "If a research study involves comparing a new
drug with a current one, and your doctor does not know
which drug is better for you. How do you feel about this?
Participant: "He'll probably try the new drug to see how it
helps me".
Interviewer: "If in a study there's a 50% chance of getting
the old drug and a 50% chance of getting the new drug,
where they'd determine which one you received in a ran-
dom manner like the lottery, would you agree to partici-
pate?"
Participant: "If I'll get better, I'll agree, why not?"
When asked regarding their thoughts about the con-
cept of equipoise, there were expressions indicating
that they would nevertheless receive the better drug:
Interviewer: "Would it matter to you though, if you got the
newer drug or the older drug, even though it's believed that
they have the same risks and benefits?
Participant: "I think my physician would know better, and
depending on their recommendation I'll take what they sug-
gest"
Interviewer: " What if the doctor doesn't know if the
Urinex or the newer drug is better for you....?"
Participant: "I'll take it if my doctor tells me that it's bet-
ter"
Interviewer:  "If it's the same study mentioned earlier,
would it matter to you if you received the old drug or the
new drug?"
Participant: "Yes it makes a big difference to me [which
drug I take].
Interviewer: "How so?"
Participant: "I'd prefer to take the old drug of course"
Responses Reflecting TM2
The following are examples of responses indicating partic-
ipants' unreasonable appraisals of the magnitude and
likelihood of benefit that one obtains from participating
in a research study:
Participant: "If the study will have a negative impact on
me, I won't participate. It must have some guidelines that
guarantee that it will protect me, so that I'll agree to partic-
ipate". Later in the same transcript:
Participant: "It's like I said, you usually won't resort to
entering a study or a [clinical] trial unless you feel like
there's something that you may gain from being in it".
Interviewer: "Would you agree to participate in a medical
research study?"
Participant:  "Certainly these studies won't have side
effects, the goal is to improve health and not cause harm".
Interviewer: "Would you allow one of your children to be
in a research study?
Participant: "I must be at least 90% reassured that it's
something safe."
Essentially, participants believed that there was good
assurance that clinical research was associated with bene-
fits or that there would be no or relatively low risks, thus
calling into question participants' understanding of the
risk/benefit ratio associated with such studies.
Discussion
The majority of the participants in this study manifested a
misconception regarding how their personal care in med-
ical research might be compromised by the procedures of
the study (TM1). A smaller number also had a misconcep-BMC Medical Ethics 2009, 10:7 http://www.biomedcentral.com/1472-6939/10/7
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tion of what is achievable in terms of benefits from the
nature of the clinical trial (TM2). According to Appelbaum
and colleagues, TM occurs "when a research subject fails
to appreciate the distinction between the imperatives of
clinical research and of ordinary treatment, and therefore
inaccurately attributes therapeutic intent to research pro-
cedures" [1]. The National Bioethics Advisory Commis-
sion (NBAC) defined TM as "the belief that the purpose of
a clinical trial is to benefit the individual patient rather
than to gather data for the purpose of contributing to sci-
entific knowledge" [17].
Commentators have hypothesized several conceptual
foundations for the presence of TM. First, potential partic-
ipants might harbor a misunderstanding of how clinical
research and patient care differ in their purpose, character-
istic methods, and justification of risks [3]. In addition to
this knowledge gap, the existence of TM could be
explained by the fact that research studies occur almost
exclusively in the clinical setting, which might reinforce
the presence of treatment relationships and individual-
ized care. Essentially, presumptions acquired by patients
in the clinical setting are brought with them to the
research setting [18]. Accordingly, many patients might
think that their care will still be individualized to match
their personal medical needs even in the context of a
research study. Such perceptions might be enhanced by
the use of certain language found in consent forms (such
as 'doctor' instead of investigator', and 'treatment' instead
of 'intervention') or when patients are recruited into clin-
ical trials by investigators who are also their primary phy-
sicians (although one study found that participants
recruited by their physicians were not more likely to
exhibit TM than others [7]).
Alternatively, many aspects of research participation
might be construed as clinical activities and therefore, par-
ticipants might see research as just another way of provid-
ing care for them [19]. For example, research activities that
include close monitoring for symptoms and side effects,
health education and psychosocial support provided by
members of the research team, and the prescribing of
medications are similar to the activities that occur in the
clinical setting. It is therefore not surprising that one study
found that many participants saw researchers as providing
better patient care than healthcare providers [19]. Finally,
the misconception may be related to emotions that partic-
ipants have towards researchers, with consequent think-
ing that researchers will act as their physicians who will
protect them as well as promote their individual health
interests [20]. Accordingly, there might be concerns about
misplaced trust towards researchers and researchers'
exploitation of such trust [11].
Our study, being exploratory in nature, used a semi-struc-
tured interview technique that involved both patients and
members of the lay public and relied on presenting hypo-
thetical clinical research scenarios to these participants.
Other empirical studies have used a variety of approaches
to assess for the presence of TM. For example, studies have
explored this phenomenon in patients who have partici-
pated in clinical trials [4-7,21] or have asked individuals
to respond to different types of hypothetical clinical
research scenarios [8-10]. These studies have also assessed
for the presence of TM in different types of clinical trials
(e.g., phase 1, 2 or 3 trials) or in different patient popula-
tions (e.g., those with cancer, psychiatric illnesses, heart
disease, and inherited diseases). Finally, studies have used
different methodologies to measure for the presence of
TM, which have included the use of focus groups sessions
[8], semi-structured interviews [4,7], survey [5], or forced
responses to discrete questions [6,21].
We believe that qualitative research design methods are
preferred when exploring the presence of and the explana-
tions that can account for TM. Such studies can perform a
more extensive probing into the reasons for the partici-
pants' TM. For example, qualitative studies can explore for
how patients view care in the research setting, their feel-
ings about the researchers juxtaposed upon those for their
primary physicians, and for the presence and type of trust
they place in researchers compared with their physicians.
Also, commentators have claimed that a concept of thera-
peutic misconception should be distinguished from that
of therapeutic misestimation, which occurs when partici-
pants understand the distinction between research and
clinical care, but their skewed estimates of risks and bene-
fits result other reasons, such as a misinterpretation of
probability information [16,22]. Quantitative methods
would fail to uncover such distinctions. Also, use of a
focus groups methodology, because it stimulates dia-
logue, might be more useful for participants who have not
thought out in detail their beliefs regarding research par-
ticipation. Finally, studies should focus separately on
members of the lay public with and without prior research
participation (using hypothetical scenarios) and patients
participating in different study trial designs and with dif-
ferent types of illnesses (e.g., acute and chronic illnesses).
Several studies have investigated the existence of partici-
pant- or study-related factors associated with the presence
of TM through multivariate analysis [4,6,7]. In a study
involving patients in different types of clinical trials, those
with greater age, lower levels of education, poorer health
and functional status, and those with greater optimism
about their health in the future were at higher risk for
manifesting TM [4]. In another study involving early
phase gene transfer trials, participants with cancer or vas-
cular diseases had lower TM scores compared with thoseBMC Medical Ethics 2009, 10:7 http://www.biomedcentral.com/1472-6939/10/7
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with inherited or infectious diseases. Also, TM scores were
significantly lower in patients when they received a con-
sistent message from the study teams and consent forms
that benefits were unlikely, compared with those who did
not receive any such messages [7].
There are two major ethical concerns with the TM. First,
failure to appreciate correctly the risks and benefits of
research participation raises concerns regarding the valid-
ity of informed consent [3,4,23]. Indeed, understanding is
an important requirement of informed consent, which
itself is fundamental to ethical clinical research. Second,
the presence of TM reflects the very real possibility that
research participants will see themselves as patients and
trust researchers as if the investigator's role was that of the
physician. The resulting concern is that patients will be
susceptible to exploitation, as investigators might take
advantage of such misplaced trust to enroll them in clini-
cal research [11,24]. The specific concern is that patients
will view an invitation to enroll in research as a profes-
sional recommendation that is intended to serve their
individual treatment interests [23].
We recognize several limitations of our study. First, the
extent with which our findings are applicable to other
populations in Egypt or other countries in the Middle East
is constrained by the small sample size and the selection
bias associated with obtaining information from only
those who agreed to participate in this interview study.
Second, the education level of our participants was higher
than the median level of Egyptians from other parts of the
country, thus questioning the applicability of our results
to other regions in Egypt. However, Appelbaum and col-
leagues [4] showed that lower educational levels were
directly associated with the presence of TM and hence,
Egyptians with lower educational levels might demon-
strate a higher prevalence of TM compared with the sam-
ple in this study. Finally, our study population was
heterogeneous, as it consisted of a mixture of patients and
the lay public and with individuals with different disease
types. However, our study was more concerned with
assessing the feasibility of performing interviews of Egyp-
tians regarding their viewpoints on clinical research. Over-
all, our findings require validation in a larger sample that
includes populations distinguished by different types of
illnesses and socio-economic variables, as well as those
who have and have not participated in clinical research.
The results of such studies can lead to targeted education
efforts focused on the underlying reasons for the presence
of TM. Several studies have shown the effectiveness of tar-
geted educational efforts in improving the comprehen-
sion and decisional capacities of research participants [25-
27], including a positive effect on TM in some groups
[28].
Conclusion
In conclusion, the presence of TM is not uncommon
amongst Egyptian individuals. Participants held a mis-
conception regarding how their personal care in medical
research might be compromised by the procedures of the
study (TM1), as well as a misconception of what is achiev-
able in terms of benefits from the nature of the clinical
trial (TM2). We recommend further qualitative studies
(both focus group discussions and in-depth interviews)
investigating aspects of TM involving a larger sample size
consisting of participants with different illnesses and
socio-economic variables, as well as those who have and
have not participated in clinical research.
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